RxDoctor Payments Data

Sudhesh Srivastava, MD

Interventional Cardiology · Brooklyn, NYNPI 1396783999

Payments from drug & device makers

$11,295in general payments, 2019–2025

Across 258 payments — averaging $43.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Novartis$783
  • Boston Scientific$751
  • Philips North America LLC$569
  • plus $6K from 34 others

What the payments were for

  • Travel & lodging$1221%
  • Food & beverage$10,90197%
  • Education$2722%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,295 in reported general payments places this provider in the 50th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$69,102
Medicare patients
413
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$129,761
FarxigaDapagliflozin Propanediol112$109,296
EntrestoSacubitril/Valsartan92$105,372
XareltoRivaroxaban70$65,110
EliquisApixaban65$59,430
VerquvoVericiguat33$44,328
OzempicSemaglutide14$12,939
BrilintaTicagrelor18$11,056
Repatha SureclickEvolocumab12$6,308
Praluent PenAlirocumab12$5,676
Nebivolol Hcl87$5,628
Valsartan164$4,431
Ezetimibe102$3,535
Ranolazine ErRanolazine48$3,338
Atorvastatin Calcium336$3,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$478$129,761131 claims
AstraZenecaFarxiga, Brilinta$1,152$120,353130 claims
NovartisEntresto$783$105,37292 claims
Johnson & JohnsonXarelto$1,046$65,11070 claims
PfizerEliquis$115$59,43065 claims
MerckVerquvo$224$44,32833 claims
Novo NordiskOzempic$27$12,93914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →